|Secondary Protocol No.
||MT1999-14 Unrelated or partially matched allogeneic donor stem cells for lymphoma, myeloma, and chronic lymphocytic leukemia
||This phase II trial is studying how well a donor stem cell transplant works in treating patients with previously treated lymphoma, multiple myeloma, or chronic lymphocytic leukemia.
||Patients will receive a preparative regimen consisting of cyclophosphamide, total-body irradiation, and possibly busulfan followed by stem cell transplantation with bone marrow or umbilical cord blood. Treatment with methotrexate and cyclosporine will be administered last to prevent post-transplant graft vs. host disease.
||Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. The donated stem cells from bone marrow or umbilical cord blood may replace the patient's immune cells and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving methotrexate and cyclosporine after transplant may prevent this graft vs. host disease.
||Patient must have confirmed diagnosis of one of the following: Chronic lymphocytic leukemia, advanced non-Hodgkin lymphoma, advanced Hogdkin disease beyond PR2 or multiple myeloma.
|Applicable Disease Sites
Chronic lymphocytic leukemia (CLL)
||Blood and Marrow Transplant
Total Body Irradiation (TBI)
CYCLOPHOSPHAMIDE (CYTOXAN, NEOSAR)
Total Body irradiation (TBI)
||Masonic Cancer Center
||Patient may be no more than 55 years of age. Must not have available histocompatible matched related donor, must not have an active uncontrolled infection. A signed informed consent and HIPAA authorization are required; assent form is also required if patient is a minor.
||Cancer Information Line nurse
Phone: 612-624-2620 - 1-888-226-2376